ArticleCancer immunology, immunotherapy : CII2023

Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.

Mussarat Wahid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.